Pharmacologic management of patients with hepatic and pancreatic diseases that involve immunosuppressive therapies. Position statement within the framework of the SARS-CoV-2 (COVID-19) pandemic. / Manejo farmacológico de pacientes con enfermedades hepáticas y pancreáticas que involucran terapias inmunosupresoras. Posicionamiento en el marco de la pandemia de SARS-CoV-2 (COVID-19).
Rev Gastroenterol Mex (Engl Ed)
; 85(3): 312-320, 2020.
Article
in English, Spanish
| MEDLINE | ID: covidwho-643614
ABSTRACT
The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus2 (SARS-CoV-2) virus. COVID-19 affected more than 6million persons worldwide in fewer than 4 months, after the report of the first cases in China in December 2019. The relation of the disease caused by SARS-Cov-2 to immunosuppressive treatment used in different gastrointestinal disorders is uncertain, resulting in debate with regard to suspending immunosuppressive therapy to improve infection outcome. Said suspension implies the inherent risk for graft rejection or autoimmune disease exacerbation that can potentially worsen the course of the infection. Based on the presently available evidence, a treatment stance has been established for patients with gastrointestinal diseases that require immunosuppressive therapy.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pancreatic Diseases
/
Pneumonia, Viral
/
Coronavirus Infections
/
Pandemics
/
Immunosuppressive Agents
/
Liver Diseases
Type of study:
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
/
Spanish
Journal:
Rev Gastroenterol Mex (Engl Ed)
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS